{"id":"https://openalex.org/W2019530565","doi":"https://doi.org/10.1517/13543784.2011.562191","title":"Lixisenatide for type 2 diabetes mellitus","display_name":"Lixisenatide for type 2 diabetes mellitus","alternate_titles":[],"publication_year":2011,"publication_date":"2011-03-11","ids":{"openalex":"https://openalex.org/W2019530565","doi":"https://doi.org/10.1517/13543784.2011.562191","mag":"2019530565","pmid":"https://pubmed.ncbi.nlm.nih.gov/21391833"},"language":"en","primary_location":{"id":"doi:10.1517/13543784.2011.562191","doi":"https://doi.org/10.1517/13543784.2011.562191","is_oa":false,"landing_page_url":"https://doi.org/10.1517/13543784.2011.562191","pdf_url":null,"source":{"id":"https://openalex.org/S131064935","display_name":"Expert Opinion on Investigational Drugs","issn_l":"1354-3784","issn":["1354-3784","1744-7658"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Investigational Drugs","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2019530565"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5051382562","display_name":"Mikkel Christensen","orcid":"https://orcid.org/0000-0002-8774-1797","observed_orcids":["https://orcid.org/0000-0002-8774-1797"]},"institutions":[{"id":"https://openalex.org/I124055696","display_name":"University of Copenhagen","ror":"https://ror.org/035b05819","country_code":"DK","type":"education","lineage":["https://openalex.org/I124055696"]},{"id":"https://openalex.org/I2802582725","display_name":"Gentofte Hospital","ror":"https://ror.org/051dzw862","country_code":"DK","type":"healthcare","lineage":["https://openalex.org/I2802567020","https://openalex.org/I2802582725"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Mikkel Christensen","raw_affiliation_strings":["University of Copenhagen, Gentofte Hospital, Diabetes Research Division, Department of Internal Medicine F, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark ; ;","University of Copenhagen, Gentofte Hospital, Diabetes Research Division, Department of Internal Medicine F, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark +45 3997 8619"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Copenhagen, Gentofte Hospital, Diabetes Research Division, Department of Internal Medicine F, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark ; ;","institution_ids":["https://openalex.org/I124055696","https://openalex.org/I2802582725"]},{"raw_affiliation_string":"University of Copenhagen, Gentofte Hospital, Diabetes Research Division, Department of Internal Medicine F, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark +45 3997 8619","institution_ids":["https://openalex.org/I124055696","https://openalex.org/I2802582725"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079352451","display_name":"Filip Krag Knop","orcid":"https://orcid.org/0000-0002-2495-5034","observed_orcids":["https://orcid.org/0000-0002-2495-5034"]},"institutions":[{"id":"https://openalex.org/I124055696","display_name":"University of Copenhagen","ror":"https://ror.org/035b05819","country_code":"DK","type":"education","lineage":["https://openalex.org/I124055696"]},{"id":"https://openalex.org/I2802582725","display_name":"Gentofte Hospital","ror":"https://ror.org/051dzw862","country_code":"DK","type":"healthcare","lineage":["https://openalex.org/I2802567020","https://openalex.org/I2802582725"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Filip K Knop","raw_affiliation_strings":["University of Copenhagen, Gentofte Hospital, Diabetes Research Division, Department of Internal Medicine F, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark ; ;","University of Copenhagen, Gentofte Hospital, Diabetes Research Division, Department of Internal Medicine F, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark +45 3997 8619"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Copenhagen, Gentofte Hospital, Diabetes Research Division, Department of Internal Medicine F, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark ; ;","institution_ids":["https://openalex.org/I124055696","https://openalex.org/I2802582725"]},{"raw_affiliation_string":"University of Copenhagen, Gentofte Hospital, Diabetes Research Division, Department of Internal Medicine F, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark +45 3997 8619","institution_ids":["https://openalex.org/I124055696","https://openalex.org/I2802582725"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004120950","display_name":"Tina Vilsb\u00f8ll","orcid":"https://orcid.org/0000-0002-0456-6787","observed_orcids":["https://orcid.org/0000-0002-0456-6787"]},"institutions":[{"id":"https://openalex.org/I124055696","display_name":"University of Copenhagen","ror":"https://ror.org/035b05819","country_code":"DK","type":"education","lineage":["https://openalex.org/I124055696"]},{"id":"https://openalex.org/I2802582725","display_name":"Gentofte Hospital","ror":"https://ror.org/051dzw862","country_code":"DK","type":"healthcare","lineage":["https://openalex.org/I2802567020","https://openalex.org/I2802582725"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Tina Vilsb\u00f8ll","raw_affiliation_strings":["University of Copenhagen, Gentofte Hospital, Diabetes Research Division, Department of Internal Medicine F, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark ; ;","University of Copenhagen, Gentofte Hospital, Diabetes Research Division, Department of Internal Medicine F, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark +45 3997 8619"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Copenhagen, Gentofte Hospital, Diabetes Research Division, Department of Internal Medicine F, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark ; ;","institution_ids":["https://openalex.org/I124055696","https://openalex.org/I2802582725"]},{"raw_affiliation_string":"University of Copenhagen, Gentofte Hospital, Diabetes Research Division, Department of Internal Medicine F, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark +45 3997 8619","institution_ids":["https://openalex.org/I124055696","https://openalex.org/I2802582725"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5085434984","display_name":"Jens Juul Holst","orcid":"https://orcid.org/0000-0001-6853-3805","observed_orcids":["https://orcid.org/0000-0001-6853-3805"]},"institutions":[{"id":"https://openalex.org/I124055696","display_name":"University of Copenhagen","ror":"https://ror.org/035b05819","country_code":"DK","type":"education","lineage":["https://openalex.org/I124055696"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Jens J Holst","raw_affiliation_strings":["Department of Biomedical Sciences, The Panum Institute, University of Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biomedical Sciences, The Panum Institute, University of Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark","institution_ids":["https://openalex.org/I124055696"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.5266,"has_fulltext":false,"cited_by_count":86,"citation_normalized_percentile":{"value":0.84120983,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":100},"biblio":{"volume":"20","issue":"4","first_page":"549","last_page":"557"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lixisenatide","display_name":"lixisenatide","score":1.0},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9990000128746033},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.9570000171661377},{"id":"https://openalex.org/keywords/glucagon-like-peptide-1","display_name":"glucagon-like peptide-1","score":0.828000009059906},{"id":"https://openalex.org/keywords/once-daily-dosing","display_name":"once-daily dosing","score":0.7599999904632568},{"id":"https://openalex.org/keywords/subcutaneous-administration","display_name":"subcutaneous administration","score":0.8500000238418579},{"id":"https://openalex.org/keywords/metformin-combination-therapy","display_name":"metformin combination therapy","score":0.8849999904632568}],"concepts":[{"id":"https://openalex.org/C2776442814","wikidata":"https://www.wikidata.org/wiki/Q6659956","display_name":"Lixisenatide","level":5,"score":0.8260781764984131},{"id":"https://openalex.org/C2910068830","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 Diabetes Mellitus","level":3,"score":0.6569759845733643},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5413624048233032},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.5105346441268921},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.49892520904541016},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4029983878135681},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.27558836340904236},{"id":"https://openalex.org/C2780533449","wikidata":"https://www.wikidata.org/wiki/Q417762","display_name":"Exenatide","level":4,"score":0.14753130078315735}],"mesh":[{"descriptor_ui":"D000067758","descriptor_name":"Glucagon-Like Peptide-2 Receptor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004353","descriptor_name":"Drug Evaluation, Preclinical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D008687","descriptor_name":"Metformin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D008687","descriptor_name":"Metformin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D010455","descriptor_name":"Peptides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D010455","descriptor_name":"Peptides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1517/13543784.2011.562191","doi":"https://doi.org/10.1517/13543784.2011.562191","is_oa":false,"landing_page_url":"https://doi.org/10.1517/13543784.2011.562191","pdf_url":null,"source":{"id":"https://openalex.org/S131064935","display_name":"Expert Opinion on Investigational Drugs","issn_l":"1354-3784","issn":["1354-3784","1744-7658"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Investigational Drugs","raw_type":"journal-article"},{"id":"pmid:21391833","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21391833","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on investigational drugs","raw_type":"Journal Article"},{"id":"pmh:oai:pure.atira.dk:openaire_cris_publications/201d3a40-cd98-49df-a88c-58cca3ec90ce","doi":null,"is_oa":false,"landing_page_url":"https://researchprofiles.ku.dk/da/publications/201d3a40-cd98-49df-a88c-58cca3ec90ce","pdf_url":null,"source":{"id":"https://openalex.org/S4306401983","display_name":"Research at the University of Copenhagen (University of Copenhagen)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I124055696","host_organization_name":"University of Copenhagen","host_organization_lineage":["https://openalex.org/I124055696"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Christensen, M, Knop, F K, Vilsb\u00f8ll, T & Holst, J J 2011, 'Lixisenatide for type 2 diabetes mellitus', Expert Opinion on Investigational Drugs, vol. 20, no. 4, pp. 549-57. https://doi.org/10.1517/13543784.2011.562191","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":37,"referenced_works":["https://openalex.org/W1506458831","https://openalex.org/W1854533075","https://openalex.org/W1909310469","https://openalex.org/W1967256054","https://openalex.org/W1968315455","https://openalex.org/W1981183973","https://openalex.org/W1982991923","https://openalex.org/W2004014076","https://openalex.org/W2020267609","https://openalex.org/W2022950672","https://openalex.org/W2033851814","https://openalex.org/W2045849794","https://openalex.org/W2058591402","https://openalex.org/W2068183831","https://openalex.org/W2088987697","https://openalex.org/W2095727732","https://openalex.org/W2095774646","https://openalex.org/W2097621088","https://openalex.org/W2098459806","https://openalex.org/W2098674879","https://openalex.org/W2101508556","https://openalex.org/W2105812875","https://openalex.org/W2106036385","https://openalex.org/W2107037013","https://openalex.org/W2111765225","https://openalex.org/W2113544353","https://openalex.org/W2119200983","https://openalex.org/W2129511851","https://openalex.org/W2129730863","https://openalex.org/W2138077952","https://openalex.org/W2146901298","https://openalex.org/W2152835319","https://openalex.org/W2164738160","https://openalex.org/W2170606300","https://openalex.org/W2172204314","https://openalex.org/W4234825176","https://openalex.org/W4285719527"],"related_works":["https://openalex.org/W2409754321","https://openalex.org/W1978569902","https://openalex.org/W1969897150","https://openalex.org/W2619128140","https://openalex.org/W1972187673","https://openalex.org/W2095994700","https://openalex.org/W2549869317","https://openalex.org/W2319963451","https://openalex.org/W2163293377","https://openalex.org/W2047140162"],"abstract_inverted_index":{"INTRODUCTION:":[0],"Type":[1],"2":[2],"diabetes":[3],"mellitus":[4],"(T2DM)":[5],"is":[6,32],"an":[7,18,168],"increasing":[8],"health":[9],"problem":[10],"worldwide.":[11],"Glucagon-like":[12],"peptide-1":[13],"(GLP-1)":[14],"receptor":[15,35,152],"agonists":[16,153],"are":[17,61,69,90,104],"expanding":[19],"drug":[20],"class":[21],"that":[22],"target":[23],"several":[24],"of":[25,29,42,54,59,129,159],"the":[26,52,57,119,143],"pathophysiological":[27],"traits":[28],"T2DM.":[30,43],"Lixisenatide":[31],"a":[33,155,163],"GLP-1":[34,151],"agonist":[36],"in":[37,102,108,111],"development":[38,68],"for":[39,56,94,170],"once-daily":[40,121],"treatment":[41,58],"AREAS":[44],"COVERED:":[45],"Pharmacological,":[46],"preclinical":[47],"and":[48,65,73,82,100,110],"clinical":[49,67],"evidence":[50],"demonstrating":[51],"applicability":[53],"lixisenatide":[55,107,130],"T2DM":[60,103],"reviewed.":[62],"Available":[63],"data":[64,117],"pending":[66],"summarized,":[70],"critically":[71],"appraised":[72],"compared":[74,148],"to":[75,87,133,139,149],"competitor":[76],"drugs.":[77],"The":[78],"most":[79],"relevant":[80],"papers":[81],"meeting":[83],"abstracts":[84],"published":[85],"up":[86],"November":[88],"2010":[89],"used":[91],"as":[92,131],"sources":[93],"this":[95],"review.":[96],"EXPERT":[97],"OPINION:":[98],"Efficacy":[99],"safety":[101],"demonstrated":[105],"with":[106,113,118,174],"monotherapy":[109],"combination":[112],"metformin.":[114],"However,":[115],"limited":[116],"intended":[120],"20":[122],"\u03bcg":[123],"subcutaneous":[124],"dosing":[125],"necessitate":[126],"further":[127],"evaluation":[128],"add-on":[132],"various":[134],"antidiabetic":[135],"treatments.":[136],"It":[137],"remains":[138],"be":[140,162],"established":[141],"whether":[142],"slightly":[144],"differing":[145],"chemical":[146],"properties":[147],"other":[150],"including":[154],"rather":[156],"short":[157],"duration":[158],"action":[160],"will":[161],"disadvantage":[164],"or":[165],"maybe":[166],"even":[167],"advantage,":[169],"example,":[171],"when":[172],"combined":[173],"long-acting":[175],"insulin.":[176]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2019530565","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":5},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":9},{"year":2015,"cited_by_count":9},{"year":2014,"cited_by_count":10},{"year":2013,"cited_by_count":23},{"year":2012,"cited_by_count":7}],"updated_date":"2026-11-19T14:11:59.513116","created_date":"2016-06-24T00:00:00"}
